WHWK

Whitehawk Therapeutics, Inc.

NASDAQ: WHWK · HEALTHCARE · BIOTECHNOLOGY

$3.92

-5.68% today

Updated 2026-06-05

Market cap

$200.78M

P/E ratio

—

P/S ratio

30.04x

EPS (TTM)

$-2.49

Dividend yield

—

52W range

$2 – $6

Volume

0.3M

Market cap

$200.78M

P/E ratio

—

P/S ratio

30.04x

EPS (TTM)

$-2.49

Dividend yield

—

52W range

$2 – $6

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$6.50

+65.82%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy2 Buy3 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-22.21M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$15.22M	$24.35M	$25.98M	$7.14M	$0.00
Net income	$-60.51M	$-65.77M	$-63.69M	$-20.60M	$-22.19M
EPS	—	—	—	—	$-2.49
Free cash flow	$-50.08M	$-63.63M	$-61.20M	$-97.98M	$-22.21M
Profit margin	-397.69%	-270.04%	-245.13%	-288.26%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
WHWK	$200.78M	27	2.7	3.0	5.0	6.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Whitehawk Therapeutics, Inc. trades at $3.92. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score.

Frequently asked questions

What is Whitehawk Therapeutics, Inc.'s stock price?

Whitehawk Therapeutics, Inc. (WHWK) trades at $3.92, on a P/S of 30.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Whitehawk Therapeutics, Inc. overvalued?

Whitehawk Therapeutics, Inc. carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Whitehawk Therapeutics, Inc. (WHWK)?

The 12-month analyst consensus target is $6.50, about 65.8% above the current $3.92. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

ir.whitehawktx.com

Quick metrics

P/S ratio30.04x

ROE-99.68%

Beta0.77

50D MA$4.13

200D MA$2.96

Shares out0.05B

Float0.02B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

WHWK vs LLY →WHWK vs JNJ →WHWK vs ABBV →Stock screener →